Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 1.00 |
| ▸ | MTOR | P42345 | 9/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.84 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.84 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.84 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.84 |
| ▸ | PRKDC | P78527 | 1/20 | 0.84 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.84 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.84 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.84 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.84 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.84 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.84 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.84 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17060446 | 0.93 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1300383 | 0.92 | PIK3CA (0.86) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| Omipalisib SCHEMBL29352875 | 0.92 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| Omipalisib SCHEMBL29358168 | 0.92 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| Omipalisib SCHEMBL623194 | 0.92 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL25495105 | 0.91 | PIK3CA (0.84) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL17833773 | 0.90 | PIK3CA (0.82) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL21964236 | 0.90 | PIK3CA (0.82) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1300553 | 0.90 | PIK3CA (0.82) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL23121496 | 0.90 | PIK3CA (0.82) | PIK3CAMTORPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120184519-A1 | Compositions and Methods for Preventing or Treating Influenza Virus Infection | THE BABRAHAM INSTITUTE | 2012-07-19 | — | — | US | claimed |
| US-10004803-B2 | Low, immune enhancing, dose mtor inhibitors and uses thereof | NOVARTIS AG (CH) | 2018-06-26 | — | — | US | disclosed |
| US-20170281753-A1 | LOW, IMMUNE ENHANCING, DOSE MTOR INHIBITORS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170274014-A1 | COMBINATIONS OF LOW, IMMUNE ENHANCING, DOSES OF MTOR INHIBITORS AND CARS | Brogdon, Jennifer (US) | 2017-09-28 | — | — | US | disclosed |
| US-20160311907-A1 | REGULATABLE CHIMERIC ANTIGEN RECEPTOR | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20160067247-A1 | NOVEL USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-03-10 | — | — | US | disclosed |
| US-20150140036-A1 | LOW, IMMUNE ENHANCING, DOSE MTOR INHIBITORS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150051215-A1 | PI3K INHIBITORS FOR TREATING FIBROTIC DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-02-19 | — | — | US | disclosed |
| US-20150031702-A1 | PI3K INHIBITORS FOR TREATING COUGH | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-01-29 | — | — | US | disclosed |
| US-20130137701-A1 | COMBINATION | GLAXOSMITHKLINE LLC | 2013-05-30 | — | — | US | disclosed |
| US-20130116267-A1 | Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-05-09 | — | — | US | disclosed |
| US-20130116267-A1 | Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-05-09 | — | — | US | disclosed |
| US-20130102595-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | CURIS, INC. | 2013-04-25 | — | — | US | disclosed |
| US-20120184519-A1 | Compositions and Methods for Preventing or Treating Influenza Virus Infection | THE BABRAHAM INSTITUTE | 2012-07-19 | — | — | US | disclosed |
| US-8138347-B2 | Quinoline derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110135655-A1 | Role of PI3K p110 delta Signaling in Retroviral Infection and Replication | PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135655-A1 | Role of PI3K p110 delta Signaling in Retroviral Infection and Replication | PIK3R5, PIK3R4, PIK3R1 | PIK3CA 10/4885MTOR 53/4885PIK3CD 5/4885 |
| US-20150031702-A1 | PI3K INHIBITORS FOR TREATING COUGH | PLA2G2C, PIK3R5, PIK3R2 | PIK3CA 22/4885MTOR 65/4885PIK3CD 12/4885 |
| US-20120184519-A1 | Compositions and Methods for Preventing or Treating Influenza Virus Infection | PIK3R5, PIK3C2A, PIK3C2B | PIK3CA 9/4885MTOR 103/4885PIK3CD 6/4885 |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | PIK3CA 1/4885MTOR 37/4885PIK3CD 5/4885 |
| US-20130137701-A1 | COMBINATION | KRAS, NQO2, QDPR | PIK3CA 1234/4885MTOR 3366/4885PIK3CD 2659/4885 |
| US-10004803-B2 | Low, immune enhancing, dose mtor inhibitors and uses thereof | RICTOR, MTOR, RPTOR | PIK3CA 64/4885MTOR 2/4885PIK3CD 73/4885 |
| US-20160311907-A1 | REGULATABLE CHIMERIC ANTIGEN RECEPTOR | CD74, HAVCR2, FCGR2A | PIK3CA 3182/4885MTOR 2743/4885PIK3CD 1546/4885 |
| US-20130102595-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | KRAS, HRAS, KSR2 | PIK3CA 31/4885MTOR 220/4885PIK3CD 194/4885 |
| US-20160067247-A1 | NOVEL USE | CFTR, MMP1, FIBP | PIK3CA 4121/4885MTOR 4383/4885PIK3CD 3866/4885 |
| US-20150140036-A1 | LOW, IMMUNE ENHANCING, DOSE MTOR INHIBITORS AND USES THEREOF | MTOR, RICTOR, RPTOR | PIK3CA 62/4885MTOR 1/4885PIK3CD 86/4885 |
| US-20150051215-A1 | PI3K INHIBITORS FOR TREATING FIBROTIC DISEASES | PIK3R5, PIK3CD, PIK3CA | PIK3CA 3/4885MTOR 32/4885PIK3CD 2/4885 |
| US-20170281753-A1 | LOW, IMMUNE ENHANCING, DOSE MTOR INHIBITORS AND USES THEREOF | MTOR, RICTOR, RPTOR | PIK3CA 62/4885MTOR 1/4885PIK3CD 86/4885 |
| US-20130116267-A1 | Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication | PIK3R5, PIK3R4, PIK3R3 | PIK3CA 10/4885MTOR 58/4885PIK3CD 6/4885 |
| US-20170274014-A1 | COMBINATIONS OF LOW, IMMUNE ENHANCING, DOSES OF MTOR INHIBITORS AND CARS | ICOS, RICTOR, CD47 | PIK3CA 286/4885MTOR 4/4885PIK3CD 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.